Maggie O'Neill

A new study has found that semaglutide, the active ingredient in the popular weight loss drugs Ozempic and Wegovy, may be linked to a type of sudden vision loss called non-arteritic anterior ischemic optic neuropathy (NAION). The study, which hasn’t […]

A majority of Americans are unaware that human papillomavirus, or HPV, can increase the risk of throat cancer, according to a recent survey.  While public health campaigns have successfully spread the word about HPV’s ability to cause cervical cancer, there’s

Eating a small amount of sugar from time to time might be better for your heart than completely eliminating it, a new study suggests. The report, published on Dec. 8 in Frontiers in Public Health, also found that the impact

Taking anti-obesity medications such as Wegovy or Zepbound might help people cut back on their alcohol consumption, new research has found. The study, published in JAMA Network Open on November 26, raises new questions about the potential benefits of these

The popularity of Ozempic, Wegovy, and other glucon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in recent years. But the cost of these medications can sometimes top $1,000 per month, putting the medications out of reach for many Americans. GLP-1s have

The Biden Administration proposed a rule on Tuesday that would require Medicare and Medicaid to cover weight loss drugs as treatments for obesity. If enacted, the policy would go into effect in 2026. Currently, these programs cover popular glucagon-like peptide-1

Popular weight management drugs like Ozempic only come in injectable form, but losing weight may soon be as easy as swallowing a pill. A slew of biopharmaceutical companies are working to create a pill version of a glucagon-like peptide 1

People with obstructive sleep apnea may be more likely to develop dementia, and the risk may be greater for women, a new study has found. The new research raises questions about how obstructive sleep apnea—which lowers a person’s oxygen levels

Americans are still spending less time outside their homes doing things like socializing and eating out than they did before the COVID-19 pandemic, new research has revealed. The study, published this week in the Journal of the American Planning Association,

Semaglutide, sold under the brand names Ozempic and Wegovy, may reduce the risk of developing Alzheimer’s in people with type 2 diabetes, a new study found. The research, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, raises